全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:... Joerg Schmitz , Michael Albrecht , Michael Staehler
来源:[J].BMC Cancer(IF 3.333), 2015, Vol.15 (1)Springer
摘要:Abstract(#br) Background(#br)Data are limited regarding routine use of everolimus after initial vascular endothelial growth factor (VEGF)–targeted therapy. The aim of this prospective, noninterventional, observational study was to assess efficacy and safety of everolimus aft...
作者:Michael Staehler , Nicolas Haseke ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2010, Vol.2010 (default), pp.191DOAJ
摘要:Michael Staehler, Nicolas Haseke, Wael Khoder, Christian G StiefDepartment of Urology, University of Munich, Klinikum Grosshadern, GermanyAbstract: Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trial temsirolimus has shown an o...
作者:Michael Staehler , Nicolas Haseke ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2010, Vol.2010 (default), pp.191-196DOAJ
摘要:Michael Staehler, Nicolas Haseke, Wael Khoder, Christian G StiefDepartment of Urology, University of Munich, Klinikum Grosshadern, GermanyAbstract: Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trial temsirolimus has shown an o...
作者:Michael Staehler , Jamal Tarazi ...
来源:[J].Clinical Genitourinary Cancer(IF 1.429), 2019, Vol.17 (3), pp.e689-e703Elsevier
摘要:Abstract(#br)Background(#br)Axitinib resulted in significantly longer progression-free survival (PFS) versus sorafenib in patients with metastatic renal-cell carcinoma (mRCC) previously treated with sunitinib in the AXIS trial. We report post hoc analyses evaluating patient subgr...
作者:Michael Staehler , Lothar Müller ...
来源:[J].Clinical Genitourinary Cancer(IF 1.429), 2018Elsevier
摘要:Abstract(#br)Introduction(#br)Since the treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved dramatically over the last decade, data on patients’ treatment and outcomes in routine practice, so called “real world data”, are important to complement c...
作者:Michael Staehler , Lothar Müller ...
来源:[J].Clinical Genitourinary Cancer(IF 1.429), 2016Elsevier
摘要:Abstract(#br)Introduction(#br)Because “real-life” patients often do not meet the strict eligibility criteria of clinical trials, we assessed the trial eligibility of patients with advanced or metastatic renal cell carcinoma (mRCC) in routine practice and compared the surviva...
作者:Michael Staehler , Motohide Uemura ...
来源:[J].The Lancet(IF 39.06), 2019, Vol.393 (10189), pp.2404-2415Elsevier
摘要:Summary(#br)Background(#br)A phase 2 trial showed improved progression-free survival for atezolizumab plus bevacizumab versus sunitinib in patients with metastatic renal cell carcinoma who express programmed death-ligand 1 (PD-L1). Here, we report results of IMmotion151, a p...
作者:Michael Staehler , Karim Bensalah ...
来源:[J].European Urology(IF 10.476), 2019, Vol.76 (2), pp.151-156Elsevier
摘要:Abstract(#br)Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Gui...
作者:... Nicolas Haseke , Christian G. Stief , Michael Staehler
来源:[J].Clinical Genitourinary Cancer(IF 1.429), 2012, Vol.10 (1), pp.37-42Elsevier
摘要:Abstract(#br)Background(#br)The outcome of patients with advanced renal cell carcinoma (RCC) under systemic therapy shows remarkable variability, and there is a need to identify prognostic parameters that allow individual prognostic stratification and selection of optimal therapy...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×